Aardvark Therapeutics, Inc.
$5.65
▲
5.13%
2026-04-21 05:00:04
aardvarktherapeutics.com
NMS: AARD
Explore Aardvark Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$114.1 M
Current Price
$5.65
52W High / Low
$17.94 / $3.35
Stock P/E
—
Book Value
$4.89
Dividend Yield
—
ROCE
-58.82%
ROE
-64.44%
Face Value
—
EPS
$-2.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
40
Beta
—
Debt / Equity
0.41
Current Ratio
10.61
Quick Ratio
10.61
Forward P/E
-1.14
Price / Sales
—
Enterprise Value
$-23.63 M
EV / EBITDA
0.38
EV / Revenue
—
Rating
Buy
Target Price
$16.9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 2. | Lantern Pharma Inc. | $2.76 | — | $27.91 M | — | -275.14% | -1.24% | $5.74 / $1.11 | $0.58 |
| 3. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 4. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 5. | NextCure, Inc. | $11.7 | — | $41.66 M | — | -145.43% | -1.11% | $15.74 / $3.85 | $9.97 |
| 6. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 7. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -18.7 M | -17.7 M | -15.85 M | -10.47 M | -9.45 M | — |
| Net Profit | -17.6 M | -16.32 M | -14.37 M | -9.31 M | -8.78 M | — |
| EPS in Rs | -0.81 | -0.75 | -0.66 | -0.43 | -0.4 | -0.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -62.73 M | -22.67 M | -6.65 M | -10.87 M |
| Net Profit | -57.59 M | -20.59 M | -7.21 M | -13.56 M |
| EPS in Rs | -2.64 | -0.94 | -0.33 | -0.62 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 117.18 M | 77.51 M | 10.54 M | 16.76 M |
| Total Liabilities | 10.55 M | 132.15 M | 45.34 M | 44.68 M |
| Equity | 106.63 M | -54.64 M | -34.8 M | -27.92 M |
| Current Assets | 111.89 M | 74.14 M | 10.37 M | 16.49 M |
| Current Liabilities | 10.55 M | 4.93 M | 1.38 M | 0.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -54.17 M | -18.09 M | -5.82 M | -10.54 M |
| Investing CF | -49.67 M | -12 M | 0 M | -1 M |
| Financing CF | 89.25 M | 81.99 M | 0 M | 0.23 M |
| Free CF | -54.27 M | -18.2 M | -5.82 M | -10.54 M |
| Capex | -0.1 M | -0.11 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -179.73% | -185.63% | 46.86% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.